HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GI 181771X

Also Known As:

GI-181771X; GI181771X

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Benzodiazepines: 8452
        GI 181771X: 3

Experts

1.	Elangbam, Chandikumar S: 1 article (01/2014)
2.	Myer, James R: 1 article (01/2014)
3.	Romach, Elizabeth H: 1 article (01/2014)
4.	Aftring, R P: 1 article (02/2008)
5.	Greenway, F L: 1 article (02/2008)
6.	Hill, J: 1 article (02/2008)
7.	Jacobson, P: 1 article (02/2008)
8.	Jordan, J: 1 article (02/2008)
9.	Kler, L: 1 article (02/2008)
10.	Leiter, L A: 1 article (02/2008)

Related Diseases

1.	Pancreatitis 01/01/2014 - "Acute (up to 2,000 mg/kg GI181771X, as single dose) and repeat-dose studies in mice and/or rats (0.25-250 mg/kg/day for 7 days to 26 weeks) showed wide-ranging morphological changes in the pancreas that were dose and duration dependent, including necrotizing pancreatitis, acinar cell hypertrophy/atrophy, zymogen degranulation, focal acinar cell hyperplasia, and interstitial inflammation. "
2.	Inflammation (Inflammations) 01/01/2014 - "Acute (up to 2,000 mg/kg GI181771X, as single dose) and repeat-dose studies in mice and/or rats (0.25-250 mg/kg/day for 7 days to 26 weeks) showed wide-ranging morphological changes in the pancreas that were dose and duration dependent, including necrotizing pancreatitis, acinar cell hypertrophy/atrophy, zymogen degranulation, focal acinar cell hyperplasia, and interstitial inflammation. "
3.	Hypertrophy 01/01/2014 - "Acute (up to 2,000 mg/kg GI181771X, as single dose) and repeat-dose studies in mice and/or rats (0.25-250 mg/kg/day for 7 days to 26 weeks) showed wide-ranging morphological changes in the pancreas that were dose and duration dependent, including necrotizing pancreatitis, acinar cell hypertrophy/atrophy, zymogen degranulation, focal acinar cell hyperplasia, and interstitial inflammation. "
4.	Hyperplasia 01/01/2014 - "Acute (up to 2,000 mg/kg GI181771X, as single dose) and repeat-dose studies in mice and/or rats (0.25-250 mg/kg/day for 7 days to 26 weeks) showed wide-ranging morphological changes in the pancreas that were dose and duration dependent, including necrotizing pancreatitis, acinar cell hypertrophy/atrophy, zymogen degranulation, focal acinar cell hyperplasia, and interstitial inflammation. "
5.	Atrophy 01/01/2014 - "Acute (up to 2,000 mg/kg GI181771X, as single dose) and repeat-dose studies in mice and/or rats (0.25-250 mg/kg/day for 7 days to 26 weeks) showed wide-ranging morphological changes in the pancreas that were dose and duration dependent, including necrotizing pancreatitis, acinar cell hypertrophy/atrophy, zymogen degranulation, focal acinar cell hyperplasia, and interstitial inflammation. "

Related Drugs and Biologics

1.	Enzyme Precursors (Zymogens)
2.	Cholecystokinin (Pancreozymin)
3.	Tablets
4.	Solutions